Scarica l'app Stockscreener
6.75
2.17%
-0.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.90
Aprire:
$6.8
Volume 24 ore:
833.86K
Relative Volume:
0.55
Capitalizzazione di mercato:
$708.01M
Reddito:
-
Utile/perdita netta:
$-57.39M
Rapporto P/E:
-4.5925
EPS:
-1.4698
Flusso di cassa netto:
$-45.79M
1 W Prestazione:
-3.02%
1M Prestazione:
+51.69%
6M Prestazione:
+239.20%
1 anno Prestazione:
+2,495%
Intervallo 1D:
$6.614
$6.8778
Intervallo di 1 settimana:
$6.6013
$7.37
Portata 52W:
$0.243
$7.51
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Nome
Relmada Therapeutics Inc
Settore
Industria
Telefono
646 876 3459
Indirizzo
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD vs PSNYW, GOODO, SHMD, DWLD, QQQE
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
4.275 | 395.46M | 2.07B | -1.42B | -1.37B | -0.6765 |
GOODO
Gladstone Commercial Corporation
|
19.65 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
5.46 | 303.59M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
44.15 | 0 | 0 | 0 | 0 | 0.00 |
QQQE
Direxion NASDAQ-100 Equal Weigh
|
99.69 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Iniziato | Piper Sandler | Overweight |
| 2026-01-23 | Ripresa | Leerink Partners | Outperform |
| 2025-12-22 | Iniziato | Jefferies | Buy |
| 2025-11-19 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-12-05 | Downgrade | Mizuho | Outperform → Neutral |
| 2024-09-17 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-06-05 | Downgrade | Goldman | Neutral → Sell |
| 2022-10-14 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-14 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-10-14 | Downgrade | Truist | Buy → Hold |
| 2022-10-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-11-18 | Iniziato | Mizuho | Buy |
| 2021-05-20 | Ripresa | Goldman | Buy |
| 2020-10-28 | Downgrade | Goldman | Buy → Neutral |
| 2020-07-14 | Iniziato | Oppenheimer | Outperform |
| 2020-05-04 | Iniziato | SunTrust | Buy |
| 2020-04-21 | Iniziato | Goldman | Buy |
| 2020-01-27 | Iniziato | Jefferies | Buy |
| 2020-01-10 | Iniziato | SVB Leerink | Outperform |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
Mostra tutto
Relmada Therapeutics Inc Borsa (RLMD) Ultime notizie
Relmada (NASDAQ: RLMD) raises $100M, adds NDV-01 and sepranolone - Stock Titan
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Zacks Investment Research
RLMD SEC FilingsRelmada Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RLMD PE Ratio & Valuation, Is RLMD Overvalued - intellectia.ai
Relmada Therapeutics (NASDAQ: RLMD) registers 33.7M shares for resale from $160M placement - Stock Titan
Relmada Therapeutics Inc. (US75955J4022.SG) analyst ratings, estimates and forecasts - uk.finance.yahoo.com
RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors - MSN
Relmada Therapeutics (RLMD) price target increased by 59.26% to 14.62 - MSN
Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See (NASDAQ:RLMD) - Seeking Alpha
With 20-plus years in drug development, Raj Pruthi joins PreveCeutical - Stock Titan
Relmada wins bullish view at Piper Sandler on cancer therapy - MSN
Here’s what makes Mizuho bullish on Relmada Therapeutics Inc (RLMD) stock - msn.com
Wall Street analysts predict a 92.19% upside in Relmada Therapeutics (RLMD): Here's what you should know - MSN
Guidance Update: How do insiders feel about Relmada Therapeutics IncQuarterly Market Summary & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know - sharewise.com
Wall Street experts anticipate a potential 92.19% increase for Relmada Therapeutics (RLMD): Key Information You Need to Know - Bitget
Portfolio Update: Should I invest in Relmada Therapeutics Inc before earningsBuy Signal & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Relmada (RLMD) Q4 2025 Earnings Call Transcript - AOL.com
RLMD stock surges 42% in a week: Here's what you should know - MSN
how Fair Value analysis spotted Relmada’s 65% gain in 2024 By Investing.com - Investing.com Canada
how Fair Value analysis spotted Relmada’s 65% gain in 2024 - Investing.com
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest - MarketBeat
Piper Sandler initiates coverage of Relmada Therapeutics (RLMD) with overweight recommendation - MSN
Here’s What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) Stock - Insider Monkey
Relmada Therapeutics (RLMD) Gains on Positive Analyst Coverage - GuruFocus
Relmada stock wins bullish view at Piper Sandler (RLMD:NASDAQ) - Seeking Alpha
Piper Sandler Initiates Relmada Therapeutics(RLMD.US) With Buy Rating, Announces Target Price $12 - Moomoo
Relmada Therapeutics (NASDAQ:RLMD) Earns Overweight Rating from Analysts at Piper Sandler - MarketBeat
Piper Sandler Initiates Coverage on RLMD with Overweight Rating - GuruFocus
Relmada Therapeutics stock initiated at Overweight by Piper Sandler - Investing.com
Short Squeeze: Is Relmada Therapeutics Inc a speculative investment2026 Stock Rankings & Growth Focused Entry Reports - baoquankhu1.vn
Relmada Therapeutics Reports Strong 2025 Results, $160M Financing, and Advances NDV-01 Bladder Cancer Program to Phase 3 - Minichart
Relmada Therapeutics Charts Aggressive Path After Earnings Call - TipRanks
Relmada Highlights NDV-01 Data, Funding in 2025 Results - TipRanks
Relmada (NASDAQ: RLMD) narrows 2025 loss, funds NDV-01 Phase 3 push - Stock Titan
Relmada Therapeutics price target raised to $19 from $10 at Mizuho - TipRanks
RLMD: Mizuho Analyst Raises Price Target to $19, Maintains Outpe - GuruFocus
VR Adviser Adds Over 1 Million Savara Shares - AOL.com
Relmada Therapeutics (NASDAQ:RLMD) Price Target Raised to $19.00 - MarketBeat
Mizuho raises Relmada Therapeutics stock price target on trial data By Investing.com - Investing.com Australia
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript - Insider Monkey
Mizuho raises Relmada Therapeutics stock price target on trial data - Investing.com
Here's Why Ovid Therapeutics Stock Popped Higher Today - AOL.com
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Relmada Therapeutics Inc (RLMD) PT Raised to $19 at Mizuho - StreetInsider
Relmada Therapeutics Inc Azioni (RLMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Relmada Therapeutics Inc Azioni (RLMD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shenouda Maged | Chief Financial Officer |
Dec 15 '25 |
Buy |
4.12 |
11,665 |
48,060 |
800,000 |
| Shenouda Maged | Chief Financial Officer |
Nov 05 '25 |
Buy |
2.20 |
500,000 |
1,100,000 |
788,335 |
| Ence Chuck | CAO and COO |
Nov 05 '25 |
Buy |
2.20 |
136,000 |
299,200 |
403,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
Nov 05 '25 |
Buy |
2.20 |
272,500 |
599,500 |
1,272,500 |
| Kelly Paul Edward | Chief Operating Officer |
Nov 05 '25 |
Buy |
2.20 |
90,000 |
198,000 |
502,295 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 27 '25 |
Buy |
0.67 |
129,455 |
86,735 |
944,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 26 '25 |
Buy |
0.62 |
80,545 |
49,938 |
814,569 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 28 '25 |
Buy |
0.74 |
55,976 |
41,422 |
1,000,000 |
| Kelly Paul Edward | Chief Operating Officer |
May 16 '25 |
Buy |
0.43 |
200,000 |
86,060 |
412,295 |
| Shenouda Maged | Chief Financial Officer |
May 19 '25 |
Buy |
0.49 |
90,000 |
43,686 |
228,335 |
0.47%
2.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):